Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295676 | 1.00 | BACE1 (1.00) | BACE1 | |
| SCHEMBL3295682 | 1.00 | BACE1 (1.00) | BACE1 | |
| SCHEMBL7927860 | 1.00 | BACE1 (1.00) | BACE1 | |
| SCHEMBL2619828 | 0.88 | BACE1 (0.78) | BACE1 | |
| SCHEMBL2931081 | 0.88 | BACE1 (0.78) | BACE1 | |
| SCHEMBL14716573 | 0.88 | BACE1 (1.00) | BACE1 | |
| SCHEMBL14716712 | 0.86 | BACE1 (1.00) | BACE1 | |
| SCHEMBL15939238 | 0.86 | BACE1 (1.00) | BACE1 | |
| SCHEMBL14733567 | 0.86 | BACE1 (1.00) | BACE1 | |
| SCHEMBL12391070 | 0.85 | BACE1 (0.74) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | claimed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | claimed |
| US-9550795-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550795-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150087637-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087637-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8933221-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933221-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933221-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, BACE2, APP | BACE1 1/4885 |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885 |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | DPYD, TPMT, QDPR | BACE1 3093/4885 |
| US-20150087637-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | DPYD, TPMT, QDPR | BACE1 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.